

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.-15. (cancelled)

16. (previously presented) An isolated polypeptide comprising a fragment of at least 17 contiguous amino acids from SEQ ID NO:2, wherein the fragment binds to WSX-1/TCCR.

17.-25. (cancelled)

26. (previously presented) An isolated polypeptide of claim 16, wherein the polypeptide comprises at least 20 contiguous amino acid residues of SEQ ID NO:2.

27. (previously presented) An isolated polypeptide of claim 16, wherein the polypeptide comprises at least 25 contiguous amino acid residues of SEQ ID NO:2.

28. (previously presented) An isolated polypeptide of claim 16, wherein the polypeptide comprises at least 30 contiguous amino acid residues of SEQ ID NO:2.

29. (previously presented) An isolated polypeptide of claim 16, wherein the polypeptide comprises at least 35 contiguous amino acid residues of SEQ ID NO:2.

30. (previously presented) An isolated polypeptide of claim 16, wherein the polypeptide comprises at least 50 contiguous amino acid residues of SEQ ID NO:2.

31. (previously presented) An isolated polypeptide of claim 16, wherein the polypeptide comprises at least 75 contiguous amino acid residues of SEQ ID NO:2.
32. (previously presented) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2.
33. (previously presented) An isolated polypeptide of claim 16, wherein the polypeptide is detectably labeled.
34. (cancelled).
35. (cancelled)
36. (cancelled)
37. (previously presented) An isolated polypeptide of claim 16, wherein the polypeptide is antigenic.
38. (cancelled)
39. (cancelled)
40. (previously presented) A composition comprising a polypeptide comprising a fragment of at least 20 contiguous amino acid residues of SEQ ID NO:2 and a pharmaceutically acceptable carrier, wherein the fragment binds to WSX-1/TCCR.
41. (withdrawn) A method of modulating an immune response in a subject comprising:

administering to a subject an effective amount of a polypeptide comprising at least 17 contiguous amino acids of SEQ ID NO:2, wherein the polypeptide has an immunomodulatory effect.

42. (withdrawn) The method of claim 41, wherein the subject is a human.
43. (withdrawn) The method of claim 41, wherein the subject has an immune disorder.
44. (withdrawn) The method of claim 41, wherein the polypeptide comprises at least 20 contiguous amino acid residues of SEQ ID NO:2.
45. (withdrawn) The method of claim 41, wherein the polypeptide comprises at least 25 contiguous amino acid residues of SEQ ID NO:2.
46. (withdrawn) The method of claim 41, wherein the polypeptide comprises at least 30 contiguous amino acid residues of SEQ ID NO:2.
47. (withdrawn) The method of claim 41, wherein the polypeptide comprises at least 35 contiguous amino acid residues of SEQ ID NO:2.
48. (withdrawn) The method of claim 41, wherein the polypeptide comprises at least 50 contiguous amino acid residues of SEQ ID NO:2.
49. (withdrawn) The method of claim 41, wherein the polypeptide comprises at least 75 contiguous amino acid residues of SEQ ID NO:2.
50. (withdrawn) The method of claim 41, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2.

51. (previously presented) An isolated polypeptide of claim 16, wherein the polypeptide is chemically modified.
52. (currently amended) An isolated polypeptide of claim 51, wherein the chemical modification is glycosylation[[,]] or phosphorylation, ~~or PEGylation~~.
53. (previously presented) An isolated polypeptide of claim 32, wherein the polypeptide is chemically modified.
54. (currently amended) An isolated polypeptide of claim 53, wherein the chemical modification is glycosylation[[,]] or phosphorylation, ~~or PEGylation~~.
55. (previously presented) An isolated polypeptide of claim 16, wherein the polypeptide comprises helix A, helix B, helix C, or helix D of IL-D80.
56. (previously presented) An isolated polypeptide of claim 16, wherein the polypeptide comprises helix A.
57. (previously presented) An isolated polypeptide of claim 16, wherein the polypeptide comprises helix D.